Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–77

Article  PubMed  Google Scholar 

Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M et al (2024) Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 42(15):1766–75

Article  PubMed  CAS  Google Scholar 

Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A et al (2021) Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant 56(5):1180–9

Article  PubMed  CAS  Google Scholar 

Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21(9):1201–12

Article  PubMed  CAS  Google Scholar 

Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S et al (2018) Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci 109(10):3235–44

Article  PubMed  PubMed Central  CAS  Google Scholar 

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D et al (2020) Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor. Clin Pharmacokinet 59(10):1273–1290

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang J, Jiang B, Li J, Liu L, Du X, Jiang H et al (2024) Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia 38(11):2410–2418

Article  PubMed  PubMed Central  CAS  Google Scholar 

McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ et al (2021) Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv 5(23):5215–9

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sexauer AN, Tasian SK (2017) Targeting FLT3 signaling in childhood acute myeloid leukemia. Front Pediatr 5:248

Article  PubMed  PubMed Central  Google Scholar 

Terao T, Matsuoka KI, Ueda H, Matsumura A, Matsubara C, Kondo K et al (2023) Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML. Blood Adv 7(5):681–6

Article  PubMed  CAS  Google Scholar 

FDA (2017) Gilteritinib for Treatment of Pediatric Patients with FLT3/ITD AML. https://www.fda.gov/media/106162/download

Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T et al (2013) Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese pediatric Leukemia/Lymphoma study group. Int J Hematol 98(5):578–588

Article  PubMed  PubMed Central  CAS  Google Scholar 

Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE et al (2023) A review of FLT3 kinase inhibitors in AML. J Clin Med 12(20):6429

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR et al (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol 18(8):1061–75

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abematsu T, Nishikawa T, Shiba N, Iijima-Yamashita Y, Inaba Y, Takahashi Y et al (2021) Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: a case report. Pediatr Blood Cancer 68(11):e29216

Article  PubMed  Google Scholar 

Leger KJ, Robison N, Narayan HK, Smith AM, Tsega T, Chung J et al (2023) Rationale and design of the Children’s Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy. Front Cardiovasc Med 10:1286241

Article  PubMed  PubMed Central  Google Scholar 

Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E et al (2023) Outcomes in patients with FLT3-Mutated Relapsed/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transpl Cell Ther 29(4):265 e1- e10

Google Scholar 

Tamefusa K, Ishida H, Kanamitsu K, Ochi M, Fujiwara K, Tatebe Y et al (2023) Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication. Pediatr Blood Cancer 70(4):e30108

Article  PubMed  Google Scholar 

Tasaka K, Kato I, Takeshita S, Yoshioka Y, Usami A, Uchihara Y et al (2023) Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatr Blood Cancer 70(5):e30185

Article  PubMed  CAS  Google Scholar 

Ata F, Benkhadra M, Ghasoub R, Fernyhough LJ, Omar NE, Nashwan AJ et al (2023) Tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials. Front Oncol 13:1285346

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jamaladdin N, Sigaud R, Kocher D, Kolodziejczak AS, Nonnenbroich LF, Ecker J et al (2023) Key pharmacokinetic parameters of 74 pediatric anticancer drugs providing assistance in preclinical studies. Clin Pharmacol Ther 114(4):904–13

Article  PubMed  CAS  Google Scholar